Assisted Reproductive Technology Market

Report Overview

In 2022, the global assisted reproductive technology market accounted for USD 31.85 billion and is expected to reach around USD 179.4 billion in 2032. Between 2023 and 2032, this market is estimated to register a CAGR of 19.4%.

Assisted reproductive technology refers to medical procedures that assist in achieving pregnancy when traditional methods are not successful. These procedures can help individuals as well as couples who are struggling with infertility, or those who may be at risk for passing on genetic disorders to their offspring.

ART includes a variety of procedures, such as in vitro fertilization, intrauterine insemination, intracytoplasmic sperm injection, & preimplantation genetic testing, among others. These procedures may involve the use of fertility medications, surgical interventions, or the uses of donated eggs, sperm, or embryos. In addition, the COVID-19 pandemic has increased the demand for ART in various sectors.

Market Scope

Product Analysis

Based on type, the market for assisted reproductive technology is segmented into instruments, accessories & disposable, and reagents & media. Among these types, the accessory & disposable segment is the most lucrative in the global assisted reproductive technology market, with a projected CAGR of 19.4%. The total revenue share of accessory & disposable-type assisted reproductive technology is 52.3% in 2022. Accessories & disposables include items such as needles, catheters, or culture dishes that are used during ART procedures and are disposed of after use. Instruments, this includes equipment such as incubators, micromanipulators, or imaging systems that are used in ART procedures. Reagents & media include the various chemicals & media that are used to support embryo development as well as culture during ART procedures.

Technology Analysis

By technology, the market is further divided into in-vitro fertilization, artificial insemination, frozen embryo transfer, and other technologies. The in-vitro fertilization segment is estimated to be the most lucrative segment in the global assisted reproductive technology market, with a market share of 87% and a projected CAGR of 19.4%, in 2022. Also, artificial insemination is another type of assisted reproductive technology that involves placing sperm directly into a woman’s cervix, uterus, or fallopian tubes, with the goal of increasing the chances of fertilization. Frozen embryo transfer is a technique used in IVF embryos that are not immediately used for implantation and can be frozen & stored for later use. Other technologies in the assisted reproductive technology market include various techniques such as gamete intrafallopian transfer, zygote intrafallopian transfer, intracytoplasmic sperm injection, and preimplantation genetic testing.

Procedure Analysis

Based on procedure, the market for assisted reproductive technology is segmented into, fresh non-donor, fresh donor, frozen donor, & frozen non-donor. Among these types, the fresh non-donor segment is the most lucrative in the assisted reproductive technology market, with a projected CAGR of 19.4%. The total revenue share of fresh non-donor-type global assisted reproductive technology is 40% in 2022. Fresh donor cycles are often used when the female partner is unable to produce viable eggs and when there is a risk of genetic transmission of certain diseases. The frozen donor procedure involves using frozen eggs and embryos from a donor or fresh sperm from the male partner or a sperm donor for fertilization. The frozen Non-Donor procedure involves using frozen eggs or embryos from the female partner and fresh sperm from the male partner for fertilization. Each procedure has its advantages or disadvantages, The most suitable procedure is chosen based on the specific needs and preferences of the couple.

End-User Analysis

Based on end-user, the market is segmented into fertility clinics, hospitals, surgical centers, clinical research institutes, and other end-users. Among these end-users, the fertility clinic segment is estimated to be the most lucrative segment in the global assisted reproductive technology market, with the largest revenue share of 40.5% and a projected CAGR of 19.4% during the forecast period. Fertility clinics are specialized medical centers that provide services related to infertility diagnosis & treatment. Hospitals provide a range of healthcare services, including assisted reproductive technology procedures. Surgical centers are specialized facilities that provide outpatient surgical procedures, including some assisted reproductive technology procedures. Clinical research institutes are dedicated to conducting research studies to develop new treatments & technologies in the field of reproductive medicine. The choice of end-user depends on various factors such as the availability of specialized services, the level of expertise as well as experience of the healthcare providers, and also the cost of the procedure.

Key Market Segments

Based on Type

• Instrument
• Sperm Separation System
• Cryosystem
• Incubator
• Imaging System
• Ovum Aspiration Pump
• Cabinet
• Micromanipulator
• Laser Systems
• Others
• Accessory & Disposable
• Reagents & Media
• Cryopreservation Media
• Semen Processing Media
• Ovum Processing Media
• Embryo Culture Media

Based on Technology

• In Vitro-Fertilization
• Artificial Insemination
• Frozen Embryo Transfer
• Other Technologies

Based on Procedure

• Fresh Donor
• Fresh Non-donor
• Frozen Donor
• Frozen Non-donor

Based on End-User

• Fertility Clinic
• Hospital
• Surgical Center
• Clinical Research Institute
• Other End-Users

Drivers

Technological advancements & rising disposable income in the ART market

Advances in medical technology, such as in vitro fertilization (IVF) and intracytoplasmic sperm injection (ICSI), have improved the success rates of ART procedures and expanded the types of patients who can benefit from them. Rising disposable income: As disposable income rises, more people are able to afford the high costs of ART procedures, making it a more accessible option for individuals and couples struggling with infertility.

Increasing awareness & Government support for the ART market

The awareness of ART options and their success rates is growing among both patients and healthcare providers, leading to increased demand for these services. Governments in some countries provide financial support for ART procedures, making them more accessible to a wider range of patients.

Restraints

There are some ethical & moral concerns surrounding ART procedures, such as the use of donor eggs or sperm, embryo selection, & surrogacy. These concerns can limit the acceptance of these procedures among some patients or healthcare providers. ART procedures can be physically & emotionally demanding for patients, requiring multiple appointments, medications, & procedures. This can be a deterrent for some patients.

Opportunity

Advancements in technology & Expansion of the ART market:

Ongoing advancements in medical technology, such as genetic testing & embryo selection, are expected to improve the success rates of ART procedures. ART expand the types of patients who can benefit from them. The ART market is expanding beyond traditional infertility treatments to include other areas, such as fertility preservation, egg freezing, and surrogacy. This expansion is creating new opportunities for growth in the market.

Increasing government support & Emerging markets:

Governments in some countries are providing financial support for ART procedures, making them more accessible to a wider range of patients. There is potential for significant growth in emerging markets, where access to ART treatments is currently limited but demand is increasing.

Trends

Growing demand for surrogacy, Surrogacy is becoming more popular as infertility rates continue to rise, & social norms change. Same-sex couples, single individuals, or those who are unable to carry a pregnancy to term due to medical conditions are turning to surrogacy as a way to have children. Growing interest in alternative treatments, there is growing interest in alternative treatments such as acupuncture, nutrition, as well as lifestyle changes to improve fertility outcomes. These treatments are being used in conjunction with traditional ART procedures to improve outcomes as well as reduce the physical and emotional toll on patients.

COVID-19 Impact Analysis

Many ART treatments were delayed or cancelled during the pandemic owing to the closure of fertility clinics & hospitals. This has led to a backlog of patients waiting for treatment as well as a potential decrease in revenue for fertility clinics. The pandemic has caused financial challenges for many people, leading to a decrease in demand for expensive ART procedures such as IVF. This has led to a potential decrease in revenue for fertility clinics and a reduction in the number of ART treatments performed. Owing to the uncertainty caused by the pandemic, many individuals are interested in preserving their fertility for the future. This has led to an increase in demand for egg & sperm freezing. Fertility clinics have implemented strict safety protocols to reduce the risk of COVID-19 transmission. This includes screening patients or staff for symptoms, wearing personal protective equipment, and implementing social distancing measures.

The COVID-19 pandemic has had a mixed impact on the ART market. While there have been challenges such as treatment delays or financial constraints, there have also been opportunities such as increased interest in fertility preservation and the use of telemedicine. As the pandemic continues to evolve, it is important for fertility clinics or providers to adapt to changing circumstances and prioritize the safety of patients as well as staff.

Regional Analysis

Europe is estimated to be the most lucrative market in the global assisted reproductive technology market, with the largest market share of 39.2%, and is expected to register a CAGR of 19.4% during the forecast period. Asia Pacific is a rapidly growing market for assisted reproductive technology, driven by increasing awareness, demand, & investment in reproductive healthcare. Countries such as China, India, and Japan have large populations and growing middle classes, which are driving demand for infertility treatment services. North America is a mature market for assisted reproductive technology, with high levels of awareness, adoption, & investment in reproductive healthcare. The Middle East & Africa are relatively underdeveloped markets for assisted reproductive technology, with limited access to healthcare services and also cultural or regulatory barriers to adoption.

Key Regions

• North America
  • The US
  • Canada
  • Mexico
• Western Europe
  • Germany
  • France
  • The UK
  • Spain
  • Italy
  • Portugal
  • Ireland
  • Austria
  • Switzerland
  • Benelux
  • Nordic
  • Rest of Western Europe
• Eastern Europe
  • Russia
  • Poland
  • The Czech Republic
  • Greece
  • Rest of Eastern Europe
• APAC
  • China
  • Japan
  • South Korea
  • India
  • Australia & New Zealand
  • Indonesia
  • Malaysia
  • Philippines
  • Singapore
  • Thailand
  • Vietnam
  • Rest of APAC
• Latin America
  • Brazil
  • Colombia
  • Chile
  • Argentina
  • Costa Rica
  • Rest of Latin America
• Middle East & Africa
  • Algeria
  • Egypt
  • Israel
  • Kuwait
  • Nigeria
  • Saudi Arabia
  • South Africa
  • Turkey
  • United Arab Emirates
  • Rest of MEA

Key Players Analysis

The market share of these key players varies depending on the region, product offerings, or competitive landscape. However, these companies are generally recognized as leaders in the assisted reproductive technology market, with strong brand recognition, extensive distribution networks, and a track record of innovation or success.

Market Key Players

• Cosmos Biomedical Ltd.
• Microm U.K. Ltd.
• CooperSurgical, Inc.
• FUJIFILM Irvine Scientific
• Cryolab Ltd.
• Vitrolife AB
• European Sperm Bank
• Bloom IVF Centre
• Merck KGaA
• Ferring B.V.
• Cook Medical Inc.
• Fujifilm Holdings Corporation
• Genea Biomedx
• Thermo Fisher Scientific, Inc.
• Millendo Therapeutics, Inc.
• Oxford Gene Technology
• Progyny Inc.
• Other Key Players

Recent Developments

• In 2020, a Team of researchers in China used CRISPR gene editing technology to genetically modify human embryos, igniting renewed debate and scrutiny around the ethics and safety of embryo editing in assisted reproductive technology.
• In 2019, California passed legislation that made it legal for doctors to donate unused embryos to research, a move that could spur innovation and advancements in the field of assisted reproductive technology.

Report Scope